samarium Sm-153 lexidronam (Quadramet)

Also Known As:

Quadramet; 153Sm-EDTMP; Sm-EDTMP; samarate(5-)-153Sm, (((1,2-ethanediylbis((nitrilo-kappa-N)bis(methylene)))tetrakis(phosphonato-kappa-O))(8-))-, pentahydrogen, (oc-6-21); samarium (153Sm) lexidronam; samarium ethylenediaminetetramethylenephosphonate; samarium-153 lexidronam; samarium-153-EDTMP

Networked: 112 relevant articles (18 outcomes, 32 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 140
- Organophosphorus Compounds: 307
  - samarium Sm-153 lexidronam: 112
- Organometallic Compounds: 69
  - samarium Sm-153 lexidronam: 112

Experts

1.	Sartor, Oliver: 3 articles (01/2018 - 02/2007)
2.	Loeb, David M: 3 articles (06/2013 - 06/2009)
3.	Dolezal, J: 3 articles (01/2007 - 01/2000)
4.	Valicenti, Richard K: 2 articles (01/2018 - 03/2011)
5.	Anderson, Peter M: 2 articles (01/2014 - 10/2005)
6.	Sinzinger, H: 2 articles (08/2011 - 06/2001)
7.	Hobbs, Robert F: 2 articles (12/2010 - 06/2009)
8.	Schwartz, Cindy L: 2 articles (12/2010 - 06/2009)
9.	Scott, Tammy: 2 articles (12/2010 - 06/2009)
10.	Sgouros, George: 2 articles (12/2010 - 06/2009)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 08/01/1995 - "Samarium-153-EDTMP is an effective agent for palliation of widespread skeletal metastases because it concentrates in bone metastases which have an osteoblastic component. " 09/01/2001 - "The present authors have developed a whole-body scintigraphic technique which is simple and reliable in calculating prospectively a safe and effective dose of 153Sm-EDTMP for palliating the patient's painful bone metastases without myelotoxicity." 09/01/1997 - "The results suggest that the 1.0 mCi/kg dose of 153Sm-EDTMP is safe and effective for the treatment of painful bone metastases." 03/01/2018 - "Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study." 11/01/2006 - "This study was to compare 3D absorbed dose calculation of 153Sm-EDTMP in treating a specified patient with bone metastasis between MC and S value methods. "
2.	Pain (Aches) 07/01/2007 - "The results of this study confirm that 153Sm-EDTMP is effective in terms of pain relief and PSA response, with minimal toxicity. " 02/01/2007 - "Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain." 12/01/1989 - "Pain was relieved in 22 of 34 evaluable patients (65%) for periods ranging from 4 to 35 weeks, following a single administration of 153Sm-EDTMP. " 12/01/2004 - "The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity associated with samarium-153-EDTMP treatment. " 07/01/2002 - "The purpose of this study was to evaluate the degree of cytological radiation damage to peripheral blood lymphocytes induced by 153Sm-EDTMP applied for palliation of metastatic bone pain. "
3.	Prostatic Neoplasms (Prostate Cancer) 01/01/2005 - "The 188Re-HEDP group included 6 patients and 25 patients, and the 153Sm-EDTMP group 6 patients and 9 patients with breast and prostate cancer, respectively. " 06/01/2001 - "Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer." 11/01/2012 - "[Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis]." 11/01/2012 - "153Sm-EDTMP is an ideal agent for the treatment of prostate cancer with bone metastasis." 06/01/2005 - "[Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases]."
4.	Neoplasms (Cancer) 05/01/1997 - "Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone." 10/01/1996 - "Biospeciation, by potentiometry and computer simulation, of Sm-EDTMP, a bone tumor palliative agent." 06/01/1995 - "[Effect of 153Sm-EDTMP on hematopoiesis and vital organs of 93 patients with bone tumor]." 08/01/1990 - "Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP." 06/01/2013 - "Prior to routine incorporation of 153Sm-EDTMP into therapeutic regimens, we must learn how to ensure optimal delivery to tumors, determine which patients are likely to benefit, improve our ability to assess clinical response in bone lesions and further evaluate the efficacy 153Sm-EDTMP in combination with chemotherapy, radiation and novel targeted agents."
5.	Osteosarcoma (Osteogenic Sarcoma) 12/01/2010 - "The authors conducted a phase 2 study to test safety and response of high-risk osteosarcoma to tandem doses of 153Sm-EDTMP and to determine correlation between radiation delivered by low and high administered activities. " 06/01/2009 - "Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma." 07/01/2012 - "This would mean that, even at high level, 153Sm-EDTMP is itself ineffective against relapsed osteosarcoma or the residual activity is too low to be active on these particular subsets of patients." 12/01/2010 - "Patients with recurrent, refractory osteosarcoma detectable on standard 99mTc bone scan received a low dose of 153Sm-EDTMP (37.0-51.8 MBq/kg), followed upon count recovery by a second, higher dose (222 MBq/kg). " 10/01/2002 - "153Sm-EDTMP and (89)SrCl(2) in a dog with spontaneous osteosarcoma."

Related Drugs and Biologics

1.	Radioisotopes (Radionuclides)
2.	Radiopharmaceuticals
3.	Samarium-153
4.	Melphalan (Alkeran)
5.	Zoledronic Acid (Zometa)
6.	Gemcitabine
7.	Docetaxel (Taxotere)
8.	Hormones (Hormone)
9.	Prostate-Specific Antigen (Semenogelase)
10.	Organophosphonates (Phosphonates)

Related Therapies and Procedures

1.	Therapeutics
2.	Castration
3.	Drug Therapy (Chemotherapy)
4.	Palliative Care (Palliative Therapy)
5.	Aftercare (After-Treatment)